Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Amyris ( AMRS) upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy. Cameron International ( CAM) upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders. EMC ( EMC) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback. East West Bancorp ( EWBC) upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback. Exelon ( EXC) upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery. Jazz Pharmaceuticals ( JAZZ) upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth. Oceaneering International ( OII) downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out. Oil States ( OIS) upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings. Rockwell Automation ( ROK) upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years. RadioShack ( RSH) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market. Vanguard Health ( VHS) rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets. Vodafone ( VOD) upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected. Vertex Pharmaceuticals ( VRTX) upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint. End of report.